Metastatic Non-Small Cell Lung Cancer
1 competing product in clinical development for Metastatic Non-Small Cell Lung Cancer.
Pipeline by Phase
Phase 31
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ramucirumab + Placebo + Erlotinib + Gefitinib + Osimertinib | Eli Lilly | Phase 3 | Active | 77 |